Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 5/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | UCHL1 | P09936 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1251244 | 0.86 | ALDH1A1 (0.47) | NPSR1LMNAPARP1L3MBTL1ALDH1A1 | |
| SCHEMBL1250055 | 0.84 | PARP1 (0.49) | NPC1PARP1 | |
| SCHEMBL4439477 | 0.81 | PARP1 (0.67) | PARP1 | |
| SCHEMBL2709309 | 0.77 | NPC1 (0.59) | NPC1USP30NPSR1LMNAMEN1 | |
| SCHEMBL204222 | 0.77 | NPC1 (0.59) | NPC1USP30NPSR1LMNAMEN1 | |
| SCHEMBL23559008 | 0.76 | NPSR1 (0.70) | NPC1USP30NPSR1LMNAMEN1 | |
| SCHEMBL15586684 | 0.76 | NPC1 (0.65) | NPC1USP30NPSR1LMNAMEN1 | |
| SCHEMBL1752674 | 0.76 | NPC1 (0.65) | NPC1USP30NPSR1LMNAMEN1 | |
| SCHEMBL6452966 | 0.76 | NPC1 (0.78) | NPC1USP30NPSR1LMNAMEN1 | |
| SCHEMBL10185597 | 0.76 | USP2 (0.66) | NPC1USP30NPSR1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261947-A1 | FUSED PYRIDAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. | 2008-10-23 | — | — | US | disclosed |
| US-7402580-B2 | Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-07-22 | — | — | US | disclosed |
| US-20050085476-A1 | Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085476-A1 | Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient | MUSK, RNASE1, DPYD | NPC1 4197/4885USP30 4036/4885NPSR1 3011/4885 |
| US-20080261947-A1 | FUSED PYRIDAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | MUSK, RNASE1, DPYD | NPC1 4228/4885USP30 3963/4885NPSR1 3032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.